From raw material to medicine

Medical cannabis today has supplemented, or even replaced, several preparations for muscle relaxation in multiple sclerosis (MS) and Parkinson’s for example. There is no reason to believe that developments will stop there.

We believe that cannabinoids will replace drugs that are often used to relieve symptoms in conditions such as tremor, cerebral palsy (CP), neuropathic pain, epilepsy, stress disorders and chronic fatigue syndrome (ME). Above all, we believe that medical cannabis can help to reduce the use of opiates in healthcare.

We are therefore developing and producing several human and veterinary medicines with active substances from extract, kief and liquid from the hemp plant Cannabis Sativa L +0.2% THC. These include raw materials and active pharmaceutical substances for the pharma sector, white labels for export, and production of sales-ready preparations under our proprietary brand.

Our goal is to halt and relieve patients’ illness symptoms with carefully formulated, clinically tested, diagnosis-specific medicines.

»In Sweden there is a lack of approved medicines with cannabinoid active substances. In actual fact there is only one approved preparation on the market today, and this is a poor show. We’re going to change that!”«

– Therese Nader, CEO Aureum Pharma AB

Drugs with different cannabinoid active substances are currently prescribed to a great many patients every year, and two health centres in Sweden have an explicit focus on medical cannabis for patients: Smärtcentrum Malmö and Spinalis in Stockholm.

Check out our careers page.

Market plan in brief

Today we have two home markets for medical cannabis: Sweden and Greece. We will then establish ourselves in the Nordic and Baltic countries; then we move on with the rest of Europe.

For the pharma industry

In our lab we extract API concentrate of high-purity liquid and kief for both research and production. We vacuum pack leaves, twigs, stalks, flowers, whole plants and residual material from a range of different cannabis strains – sativa, indica or hybrids.

Quality assurance

All our production takes place in line with Good Manufacturing Practice (GMP), Good Distribution Practice (GDP), Good Laboratory Practice (GLP).

Aureum Pharma in brief

We develop and produce life-improving medicines from extract, kief and liquids from hemp plants. The preparations are packed under our own brand, and as white label products for distribution worldwide.